灯盏花素治疗急性心肌梗死对超敏C-反应蛋白的影响及疗效分析  

Analysis of clinical effect of Brevisapine injection on high sensitivity C-reaction protein level in the treatment of acute myocardial infarction.

作　　者：左鹰[1] 贾瑞珍[2] 于东明[1] 

机构地区：[1]首都医科大学附属北京天坛医院急诊科,100050 [2]北京建筑工程学院卫生所

出　　处：《中国综合临床》2009年第3期291-293,共3页Clinical Medicine of China

摘　　要：目的探讨灯盏花素治疗急性心肌梗死（AMI）对超敏C-反应蛋白（hs—CRP）的影响及疗效分析。方法将符合入选条件的患者随机单盲分为治疗组（80例）和对照组（80例）；2组均给予常规治疗，治疗组同时用注射灯盏花素100mg加生理盐水250ml静脉滴注，1次/d，连续用药14d。选择同期就诊者80例做健康对照组。采用酶联免疫吸附法（ELLSA法）分别在第2、7、14天检测治疗组、对照组、健康对照组hs—CRP水平。分析2组患者治疗后的的病死率、心功能状态（Killip分级）、梗塞血管再通率和发病后4周内临床心脏不良事件发生率（梗塞后心绞痛、新发心律失常、再次梗死发生率及出血发生率）。结果治疗组患者治疗第2天血清中hs—CRP水平较健康对照组明显增高[（6．37±1．43）、（2．17±1．12）mmol／L]，2组比较差异有统计学意义（P均〈0．01）；治疗组在第7、14天血清hs-CRP水平[（3．21±1．31）、（2．25±0．34）mmol／L]较对照组[（5．87±1．16）、（3．97±1．21）mmol／L]明显降低，2组比较差异有统计学意义（P均〈0．01）；治疗组与对照组梗塞血管再通率分另q为62．50％（50／80）、51．25％（45／80），2组比较差异有统计学意义（P〈0．01）。2组病死率分别为3．75％和4．10％，差异无统计学意义（P〉0．05）；出血发生率分别为6．25％和7．50％，差异无统计学意义（P〉0．05）；心功能Killip分级≤Ⅱ级2组分别为83．75％和61．25％，差异有统计学意义（P〈0．05）。治疗组4周后心脏不良事件发生率明显低于对照组，差异有统计学意义（P〈0．01）。治疗组未见明显不良反应。结论血清hs-CRP水平与AMI密切相关，是AMI的危险因素；灯盏花素治疗AMI具有一定的疗效及安全性，其机制可能与灯盏花素降低患者血清hs-CRP水平，抑制AMI的血管炎性反应有关。Objective To analyze the clinical effect of brevisapine injection on high sensitivity C-reaction protein level in the treatment of acute myocardial infarction. Methods The patients were randomly divided into treatment group（ n = 80） and control group（ n = 80）. Both groups were treated with routine midication, hut treatment group were given intravenous drip of 100 mg brevisapine once a day,for 14 days. 80 paients who came for diagnosis were selected for healthy control group. The serum high sensitivity C-reaction protein levels were measured at 2 d, 7 d,and 14 d by ELLSA in treatment group ,control group and healthy control group. Mortality,heart function status （Killip class）, revascularization and clinical adverse cardic events including postinfartion angina , new arrhythmia, reinfarction and bleeding complication at 4 weeks were observed. Results Treatment group had a significantly high level of hs-CRP compared with healthy subjects [ （6.37 ± 1.43 ） vs. （2.17 ± 1.12） mmol/L, P 〈 0.01 ] at the second day. The serum hs-CRP content of treatment group was obviously lower than that of control group（3.21 ± 1.31 ） and （2.25 ±0.34）mmoL/L vs. （5.87 ±1.16）,（3.97 ± 1.21）mmol/L,（P 〈0.01） ] on the 7th ,14th days; The revascularization rate of treatment group was obviously higher than that of control group [ 62.50% （50/80） vs.51.25% （45/80）,P 〈 0.01 ] ;There was no difference between the two groups in mortality （3.75% vs. 4.10%, P 〉0.05）. No difference was found in the rate of bleeding between the two groups（6.25% vs. 7.50% ,P 〉0.05） ; Patients with Killip class ≤ Ⅱof treatment group was obviously higher than that of control group （83.75% vs 61.25% ,P 〈 0.05 ） ; Clinical adverse cardic events rates at 4 weeks of treatment group were obviously lower than those of control group （P 〈 0.01 ）. No obvious adverse reactions related to the treatment group were observed. Conclusion The serum hs-CRP level is in close relation with acute myocardial

关 键 词：灯盏花素 急性心肌梗死 超敏C-反应蛋白 

分 类 号：R259[医药卫生—中西医结合]